Regarding IL-10, there was absent or weak (0–1) staining in eight (57.1%) benign tumors and 1 (7.1%) malignant tumor, and moderate or strong (2–3) staining in six (42.9%) benign tumors and 13 (92.9%) malignant tumors. Here, IL10 is linked to benign neoplasm.